万洲国际平台(CHN)有限公司-BinG百科 NO.1-1

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

03-182024

Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM

GUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing i...
02-012024

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis

Guangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline o...
01-032024

Bio-Thera Solutions Partners with Macter International to Market BAT1706, an Avastin®1 biosimilar, in Pakistan and Afghanistan

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline ...